Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
Blocking the immunoinhibitory PD-1:PD-L1 pathway using monoclonal antibodies has led to dramatic clinical responses by reversing tumor immune evasion and provoking robust and durable antitumor responses. Anti-PD-1 antibodies have now been approved for the treatment of melanoma, and are being clinica...
Main Authors: | Aaron Prodeus, Aws Abdul-Wahid, Nicholas W Fischer, Eric H-B Huang, Marzena Cydzik, Jean Gariépy |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-01-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253116300233 |
Similar Items
-
Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers
by: Qiping Jiang, et al.
Published: (2024-01-01) -
A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
by: Wei-Yun Lai, et al.
Published: (2016-01-01) -
Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival
by: Aaron Prodeus, et al.
Published: (2014-01-01) -
Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo
by: Yacong An, et al.
Published: (2022-02-01) -
Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles
by: Xialian Lai, et al.
Published: (2023-03-01)